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Crohn disease (CD) is an inflammatory bowel disease (IBD), wherein the involvement of gastrointestinal tract (GIT) is transmural and any part of GIT can be affected. 
Pediatric CD (PCD) is being reported with an increased incidence 
recently, even in India [1]. It is more severe in children than in 
adults, both in presentation and evolution, a fact that should alert 
the physician for an early diagnosis. Growth failure is a major 
complication in children. Impaired growth velocity can occur 
before gastrointestinal symptoms in majority of children with 
CD [2]. We describe here four such cases where undernutrition 
and short stature constituted the clinical spectrum along with 
enteric features. These early considerations of biologicals in the 
management of PCD prevent morbidity and mortality to certain 
extent.
CASE REPORT
Four children were diagnosed and followed up between 2015 
and 2018 in a tertiary care center where pediatric surgery and 
gastroenterology specialty clinics are available. Informed written 
consent was taken from all the parents for scientific publication. 
Tabular representations of all the cases are given in Table 1. 
Diagnosis of CD was based on clinical presentation, laboratory 
tests, and colonoscopy with biopsy. The median age of presentation 
was 13 years. The average duration between onset of symptoms and 
diagnosis in our case series was 2 years. The presenting symptoms 
were intermittent abdominal pain associated with growth failure 
in all cases. All had body mass index of the <3rd centile as per the 
World Health Organization classification. The examination was 
marked for anemia (Mean hemoglobin – 7.9 g/dl) and clubbing. 
Alopecia was present in one child.
Two children were positive for anti-saccharomyces cerevisiae 
IgA (ASCA) antibodies. Contrast-enhanced computed tomography 
abdomen and colonoscopy (Fig. 1) showed classical features 
of CD, as mentioned in the table. Short segment involvement 
was noted in one child, whereas long segment thickening from 
jejunum to descending colon was present in the rest of the cases. 
Two of them had strictures in the ileum while cecal and perianal 
fistula were present in one child. Biopsy showed non-caseating 
granulomatous inflammation with cryptitis, crypt distortion, and 
crypt abscess in a majority of children.
As the symptomatology and clinical features were mimicking 
intestinal tuberculosis, a prevalent disease in our country, diagnosis 
of CD was delayed contributing to increased morbidity [3]. Three 
of our cases received antituberculosis therapy (ATT) before the 
diagnosis of CD. Individualized treatment was planned for each 
child where, mesalamine (70 mg/kg/day), a 5-aminosalicylic 
acid agents were the first-line drug used in all the cases. Oral 
prednisolone (2 mg/kg/day) was added to the regimen when 
the response was poor. Only one child went into remission with 
oral steroids. Azathioprine (2 mg/kg/day) constituted second-
line management in the rest three cases. Crisis management 
included antibiotics such as ciprofloxacin (20 mg/kg/day) and 
metronidazole (30 mg/kg/day), hydration, and enteral nutrition 
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which included high-protein diet formula (100 k.cal/kg/day) and 
probiotics.
Disease activity as per abbreviated PCD activity index 
(abbreviated PCDAI) after 2 months of therapy was ranging 
between 10 and 30 with a mean score of 17 (abbreviated pediatric 
Crohn’s disease activity index [PCDAI] <10 indicates remission), 
signifying the need for biological [4]. Due to financial constraints 
and irregular follow-up, biologicals were not started initially in 
three of the cases; whereas, one child succumbed to illness due to 
dilated cardiomyopathy. Recurrent intussusceptions and need for 
multiple packed RBC transfusions due to microbleeds in the large 
intestine, one girl needed surgical intervention. Two children 
received adalimumab (loading dose of 80 mg; subsequent doses 
at 40 mg given subcutaneously once in 15 days) and are on regular 
follow-up.
Figure 1: Multiple ulcerations and pseudopolyps noted in ascending 
colon associated with thickened ileocaecal valve
Table 1: Clinical profile, investigations, and outcome
Clinical details Case 1 (Male, 13 years) Case 2 (Female, 
13 years)
Case 3 (Male, 
17 years)
Case 4 (Male, 
11 years)
Clinical profile
Recurrent abdominal pain + + + +
Melena/hematochezia - + - -
Growth failure + + + +
Anemia + + + +
Clubbing − + + +
Alopecia − − − +
Oral ulcers + + + +
Hepatomegaly + + + -
Investigations
1. Abdominal imaging findings (CECT/MRI)
Segment thickening Long Long Long Short
Increase mesenteric vascularity + + + +
Comb sign - + + −
Mesenteric lymphadenopathy + + + +
2. Colonoscopy
Pseudopolyps + + + +
Mucosal ulcers + + + −
Skip lesions − − + +
3. Biopsy
Granulomas − + + −
Crypt distortion + + + −
4. ASCA Negative Positive Negative Positive
Empirical ATT + + − +
Response to oral steroids Poor Poor Poor Good
PCDAI after 2 months of treatment 15 30 15 10
Adalimumab − + + −
The course of the disease Cardiomyopathy with EF=25% Recurrent intussusceptions 
underwent right 
hemicolectomy
Recurrent 
symptoms, anemia, 
hypoalbuminemia
Receiving growth 
hormone therapy
Outcome Died secondary to dilated 
cardiomyopathy
Asymptomatic with good 
weight gain
Asymptomatic 
average weight 
gain
Asymptomatic
ASCA: Anti‑saccharomyces cerevisiae IgA, ATT: Antituberculosis therapy, PCDAI: Pediatric Crohn’s disease activity index, MRI: Magnetic resonance imaging, 
CECT: Contrast‑enhanced computed tomography
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DISCUSSION
Incidence of PCD has been rising in both developed and developing 
countries [5,6]. Of all cases of CD, 15–25% occurs in pediatric 
population [6]. Commonage of onset is during preadolescence 
and young adulthood. PCD can involve any part of GIT, most 
commonly terminal ileum and right colon. The common clinical 
features include constellation of abdominal pain, diarrhea, 
growth failure, weight loss, poor appetite, and unexplained fever. 
However, most characteristic symptoms include insidious onset 
of abdominal pain and weight loss. Growth failure can be an 
important initial clue in suspecting PCD since approximately half 
of the children have a delay in height velocity, before obvious 
intestinal manifestation, as seen in our case series [7]. Findings 
on physical examination such as pallor and abdominal tenderness 
are not specific; however, abdominal mass, aphthous ulcers, 
erythema nodosum, digital clubbing, arthritis, or perianal tags are 
highly suggestive of CD.
A positive ASCA test in children with IBD is suggestive of 
CD (sensitivity 49% and specificity 97%) [8]. Radiographic 
features include narrowing of the lumen of the small intestine or 
colon with ulceration, string sign, fistulae, and abscess formation 
which were present in all of our cases. Colonoscopic features 
range from subtle focal aphthoid ulcers to diffuse areas of edema 
and ulceration that creates a polypoid mucosa (Fig. 1) and give 
a cobblestone appearance. Skip lesions, pseudopolyps with 
traversing mucosal ulcers are key features of CD [9]. Intestinal 
complications contribute to significant morbidity in PCD. They 
include fistulae between different segments of bowel or from 
bowel to adjacent organs, abdominal abscess, intussusceptions, 
small bowel obstruction, and localized peritonitis. One child had 
recurrent intussusceptions requiring surgery in our case series. 
Most common extraintestinal complications in PCD include 
arthritis, aphthous stomatitis, and osteopenia [10]. Alopecia 
was present in one child which is a less frequent manifestation 
associated with CD [11]. One child succumbed to illness 
secondary to dilated cardiomyopathy, a rare complication noted 
in PCD [12].
Antitumor necrosis factor agents are used in children with 
steroid-refractory IBD or in combination with immunomodulators, 
as dual therapy, are more effective than single agent alone. 
These agents are considered superior to immunomodulators and 
induce complete mucosal healing of intestine. In children with 
severe mucosal ulcerations, perianal fistulas, and/or significant 
growth failure, these are considered as the first-line agents [13]. 
Remission in PCD on biological therapy is reported as 50% by 
the end of the 1st year with reasonable safety profile [14]. Two 
children were started on adalimumab therapy. Good therapeutic 
response was noted, wherein abdominal pain, decreased need for 
blood transfusions, and weight gain were documented.
A decline in the growth chart percentiles for weight and height 
with respect to the age and gender should arouse suspicion of 
an underlying systemic disease. Growth failure can precede 
gastrointestinal symptoms in CD, needing thorough evaluation. 
An early diagnosis is of prime importance in managing these 
children, thereby preventing morbidity associated with the 
disease.
CONCLUSIONS
Diagnosis of CD needs to be considered in children where initial 
diagnosis of intestinal tuberculosis was made and had poor 
response to ATT. Considering biologicals early in CD can help in 
altering the prognosis of CD.
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